Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 3, 2014, Pages 676-683

  Gutierrez, Maria J ^a   Rosenberg, Noah L ^b   Macdougall, Diane E ^b   Hanselman, Jeffrey C ^b   Margulies, Janice R ^b   Strange, Poul ^c   Milad, Mark A ^d   Mcbride, Scott J ^e   Newton, Roger S ^b  

^a Comprehensive Clinical Development ^*  (United States)

^b Esperion Therapeutics Inc   (United States)

^c Integrated Medical Development LLC   (United States)

^d Milad Consulting   (United Kingdom)

^e UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Cardiovascular diseases; Lipid and lipoprotein metabolism; Low density lipoprotein cholesterol; Risk factors; Type 2 diabetes mellitus

Indexed keywords

CARDIOVASCULAR DISEASES; LIPID AND LIPOPROTEIN METABOLISM; LOW-DENSITY LIPOPROTEIN-CHOLESTEROL; RISK FACTORS; TYPE 2 DIABETES MELLITUS;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84894573802     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302677     Document Type: Article

References (19)

1. Center for Disease Control and Prevention. Diabetes Report Card 2012. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2012. www.cdc.gov/diabetes/pubs/pdf/ diabetesreportcard. pdf. Accessed September 26, 2013
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. www. cdc.gov/diabetes/pubs/ factsheet11.htm. Accessed September 26, 2013
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239
4. Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: A retrospective database analysis. Cardiovasc Diabetol. 2009;8:26
5. Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: Rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008;9:669-676
6. Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007;13:652-663
7. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172:144-152
8. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209-1216
9. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Canon CP. High-dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract). Circulation.2004;110:S834
10. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet. 2010;375:735-742
11. Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, Mehta JL. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009;57:495-499
12. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107:387-392
13. USFDA FDA Drug Safety Communication. Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. http://www.fda.gov/drugs/drugsafety/ ucm293101.htm. Accessed September 16, 2013
14. Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS. AMP-Activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134-151
15. Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, Srivastava RA, Hurley TR, Bradshaw CD, Spahr MA, Newton RS. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013;54:2095-2108
16. Srivastava RAK, Hurley TR, Brant AF, Bradshaw CD, Hanselman JC, Baker C, Naples M, Adeli K, Newton RS. A Novel Small Molecule, ETC-1002, Lowers Proatherogenic Lipoproteins, Reduces Adiposity, and Improves Hepatic Steatosis in a Hyperlipidemic Hamster Model. Orlando, FL: American Heart Association Scientific Sessions. 2011. Abstract# 25085
17. Hanselman JC, Bradshaw CD, Brant AF, Cramer CT, Hurley TR, Pinkosky SL, Spahr MA, Washburn JG, Newton RS, Srivastava RAK. ETC-1002 Reduces Circulating and Hepatic Triglyceride Content and Improves Glycemic Control in KKAy Mice. Chicago, IL: American Heart Association: Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions. 2011. Abstract# 657
18. Cramer CT, Goetz B, Hopson KL, Fici GJ, Ackermann RM, Brown SC, Bisgaier CL, Rajeswaran WG, Oniciu DC, Pape ME. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res. 2004;45:1289-1301
19. Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-Activated protein kinase in subjects with hypercholesterolemia: Results of a double-blind, parallel group, multicenter, placebo controlled trial. J Am Coll Cardiol. 2013;62:1154-1162